About

About

We are medical technology products company. We have developed a range of intensive care devices for mid-segment markets by undertaking in-house design and development activities. We are committed to good quality by designing and testing our products to meet international performance & reliability standards.

Overview

We are a medical technology products company focused on the research, design and development, manufacturing, and distribution of intensive care unit, or ICU devices, and commercialization of innovative soft-tissue core biopsy systems.

We operate in two business segments within the medical device industry: Intensive-care devices used in critical care areas in hospitals and Soft-tissue core biopsy systems used in definitive diagnosis for infective and cancer pathologies.

We have developed a range of ICU devices for mid-tier markets in India: primarily consisting of small and mid-sized hospitals and markets in emerging and developing countries. These product ranges include syringe pumps, infusion pumps, a range of multi-parameter patient monitors, and mechanical ventilators for different care areas. We have integrated market-validated, world-class OEM technologies in our designs and optimized the supply chain to offer customizable products to meet the changing demands of our mid-range healthcare facility customer base.

Our subsidiary IndioLabs is developing an innovative, organ-specific, soft-tissue core biopsy system that combines three patented technologies. We are addressing the shortcomings of existing core biopsy devices, such as the Tru-Cut needle-based biopsy devices. We believe our patented technologies simplify the complex biopsy procedure largely restricted to tertiary care healthcare facilities. In doing so, we believe our technologies have the potential to unleash latent and early demand for biopsy tissue-based definitive diagnostics in secondary care facilities as well.

We intend to sell our products primarily to distributors, hospitals, clinics, government agencies, OEM, and ODM customers. We are establishing nationwide distribution, sales, and service networks in India. In addition, we intend to expand sales of our products internationally, through distributors, and with OEM and ODM customers that will enhance our market position globally.

Our strategic objective is to establish and strengthen our position as a leader in intensive care devices in India and become a forerunner in selected international markets. We believe we have the following principal competitive strengths

Strong research and design capabilities: We have efficiently developed a new range of patient monitoring systems, infusion systems and developing a new range of state-of-the-art mechanical respiratory ventilators in cooperation with OEM respiratory module suppliers. These devices are already tested for performance and safety and are under the regulatory compliance certification phase.

Commitment to Innovation: Our subsidiary IndioLabs has progressively achieved significant improvements in our BioScoopTM biopsy system. Our in-house team of experts is closely associated with healthcare professionals practicing their art in our chosen market segments. With our specialized training and direct clinical observations, we have insights for identifying and validating the most compelling needs in clinical practice. Starting with liver biopsy, our entire portfolio of the BioScoop biopsy system catering to five independent organs developed in-house within the last four years.

Product development strategy: We have developed range of intensive care devices with a deep understanding of the requirements of mid-range hospitals. In doing so, we believe we have integrated the best OEM technologies and sub-systems into our designs to efficiently deliver high levels of clinical performance at a competitive price. As a result of modular design, the integration of these sub-systems is inherently customizable. Our base units are contract manufactured in bulk, and we integrate with additional components in our manufacturing facility as per customization request orders, which leads to lower inventory levels throughout the supply chain while simultaneously allowing us to achieve economies of scale.

Our business model: We are developing an e-commerce portal for customer engagement and conducting sales and service activities. We aim to improve the affordability, accessibility, and availability of devices to these Tier-II hospitals by initiating a “devices-as-service” program by providing our equipment on lease/rent rather than outright sales. We plan to explore this business model and optimize it as we go forward with real market insights. We believe that this business model would create an enhanced market opportunity in mid-tier healthcare in India. This business model may also call for minor changes in products for service enablement and to effectively manage the devices.

To be competitive in an innovative and knowledge-intensive medical device industry, we have invested heavily in creating a robust intellectual property portfolio of design and utility patents that is being actively expanded and protected worldwide.

We have a robust intellectual property portfolio, including design patents and utility patents. Thirteen design patents are granted in India for our portfolio of intensive care devices. Aesthetic and Important design features, graphic user interfaces are designed in-house and protected through these design registrations.

Our subsidiary, Indio Labs, has obtained exclusive, worldwide licenses to granted and pending patent applications in multiple geographies around the globe. As of June 2021, our intellectual property portfolio comprises rights to three patents in India. Internationally, we hold rights to Eleven granted patents in the USA, China, EU, Canada, Japan, and ARIPO region.

We are further pursuing multiple patent-pending applications, including one each in Japan and Canada, two in the USA, China, ARIPO, and Europe. We also have thirteen registered design patents and ten design applications in India.

We intend to continue our aggressive efforts in expanding, protecting, and defending our intellectual property rights, both within India and globally.

Notice: All logos, trademarks are registered trademarks of their respective owners.
Our Business

We are a medical technology products company focused on the research, design and development, manufacturing, and distribution of intensive care unit, or ICU devices, and commercialization of innovative soft-tissue core biopsy systems.

We operate in two business segments within the medical device industry: Intensive-care devices used in critical care areas in hospitals and Soft-tissue core biopsy systems used in definitive diagnosis for infective and cancer pathologies.

We have developed a range of ICU devices for mid-tier markets in India: primarily consisting of small and mid-sized hospitals and markets in emerging and developing countries. These product ranges include syringe pumps, infusion pumps, a range of multi-parameter patient monitors, and mechanical ventilators for different care areas. We have integrated market-validated, world-class OEM technologies in our designs and optimized the supply chain to offer customizable products to meet the changing demands of our mid-range healthcare facility customer base.

Our subsidiary IndioLabs is developing an innovative, organ-specific, soft-tissue core biopsy system that combines three patented technologies. We are addressing the shortcomings of existing core biopsy devices, such as the Tru-Cut needle-based biopsy devices. We believe our patented technologies simplify the complex biopsy procedure largely restricted to tertiary care healthcare facilities. In doing so, we believe our technologies have the potential to unleash latent and early demand for biopsy tissue-based definitive diagnostics in secondary care facilities as well.

We intend to sell our products primarily to distributors, hospitals, clinics, government agencies, OEM, and ODM customers. We are establishing nationwide distribution, sales, and service networks in India. In addition, we intend to expand sales of our products internationally, through distributors, and with OEM and ODM customers that will enhance our market position globally.

Core Competencies

Our strategic objective is to establish and strengthen our position as a leader in intensive care devices in India and become a forerunner in selected international markets. We believe we have the following principal competitive strengths

Strong research and design capabilities: We have efficiently developed a new range of patient monitoring systems, infusion systems and developing a new range of state-of-the-art mechanical respiratory ventilators in cooperation with OEM respiratory module suppliers. These devices are already tested for performance and safety and are under the regulatory compliance certification phase.

Commitment to Innovation: Our subsidiary IndioLabs has progressively achieved significant improvements in our BioScoopTM biopsy system. Our in-house team of experts is closely associated with healthcare professionals practicing their art in our chosen market segments. With our specialized training and direct clinical observations, we have insights for identifying and validating the most compelling needs in clinical practice. Starting with liver biopsy, our entire portfolio of the BioScoop biopsy system catering to five independent organs developed in-house within the last four years.

Product development strategy: We have developed range of intensive care devices with a deep understanding of the requirements of mid-range hospitals. In doing so, we believe we have integrated the best OEM technologies and sub-systems into our designs to efficiently deliver high levels of clinical performance at a competitive price. As a result of modular design, the integration of these sub-systems is inherently customizable. Our base units are contract manufactured in bulk, and we integrate with additional components in our manufacturing facility as per customization request orders, which leads to lower inventory levels throughout the supply chain while simultaneously allowing us to achieve economies of scale.

Our business model: We are developing an e-commerce portal for customer engagement and conducting sales and service activities. We aim to improve the affordability, accessibility, and availability of devices to these Tier-II hospitals by initiating a “devices-as-service” program by providing our equipment on lease/rent rather than outright sales. We plan to explore this business model and optimize it as we go forward with real market insights. We believe that this business model would create an enhanced market opportunity in mid-tier healthcare in India. This business model may also call for minor changes in products for service enablement and to effectively manage the devices.

Intellectual Property

To be competitive in an innovative and knowledge-intensive medical device industry, we have invested heavily in creating a robust intellectual property portfolio of design and utility patents that is being actively expanded and protected worldwide.

We have a robust intellectual property portfolio, including design patents and utility patents. Thirteen design patents are granted in India for our portfolio of intensive care devices. Aesthetic and Important design features, graphic user interfaces are designed in-house and protected through these design registrations.

Our subsidiary, Indio Labs, has obtained exclusive, worldwide licenses to granted and pending patent applications in multiple geographies around the globe. As of June 2021, our intellectual property portfolio comprises rights to three patents in India. Internationally, we hold rights to Eleven granted patents in the USA, China, EU, Canada, Japan, and ARIPO region.

We are further pursuing multiple patent-pending applications, including one each in Japan and Canada, two in the USA, China, ARIPO, and Europe. We also have thirteen registered design patents and ten design applications in India.

We intend to continue our aggressive efforts in expanding, protecting, and defending our intellectual property rights, both within India and globally.

Notice: All logos, trademarks are registered trademarks of their respective owners.

Vision

Omya shall be recognized for its ability to offer need-based medical technology solutions that enable healthcare providers to deliver safer, efficacious and value-appropriate outcomes. We will strive to accomplish this by the creative pursuit of innovation, design, and value creation for all stakeholders across the healthcare delivery continuum.

Mission

By the year 2025, Our mission is to establish Omya as a thought leader in the Indian medical device ecosystem. Our medium-term strategic objective is to strengthen our position as a leader in intensive care devices in India and to become a forerunner in selected international markets.

Partners and Collaborations

We believe that partnerships and collaborations are key requirements for inclusive innovation, and we have cultivated deep relationships with technology partners, clinical partners and hospitals, development partners, and suppliers.

Omya has integrated best and clinically proven Masimo technologies to provide enhanced clinical capabilities in our patient monitoring systems. Accurate sensing and signal processing are necessary components of any patient monitoring system, and Masimo is an innovator in this area for noninvasive and continuous SpO2 monitoring for neonate and in critical care settings.

https://www.masimo.com/oem/partners/omya/

Omya has also integrated Masimo’s (formerly: Phasein, Sweden) Capnography and Multigas monitoring technologies into its range of high-end patient monitoring systems. These systems measure respiratory gases in a wide range of clinical applications reliably thus improving patient outcomes.

Omya’s new critical care ventilator is developed with the advanced module from Demcon Macawi respiratory systems, The Netherlands. These modules are integrated into two models of neonate and critical care ventilators for invasive and non-invasive ICU and sub-acute care areas.

Notice: MasimoSET® and Demcon® are registered trademarks of their respective owners, mentioned hereunder in Purchasing and Licensing Agreement.

We believe that partnerships and collaborations are key requirements for inclusive innovation, and we have cultivated deep relationships with technology partners, clinical partners and hospitals, development partners, and suppliers.

Through our subsidiary, Indio Labs Private Limited, we have a long-standing association with key opinion leaders in the specialty areas of gastroenterology, urology, nephrology, oncology, critical care, and pediatrics at leading academic medical centers in India and internationally.

These include physician mentors at world-class institutions including The All India Institute of Medical Sciences (New Delhi, India), Stanford Clinics and Hospitals (Stanford University, USA), Johns Hopkins University (Baltimore, USA), National University Hospitals (Singapore), St. John’s Hospital and Research Center (Bangalore, India) and Translational Health Sciences and Technology Institute (Faridabad, India).

We owe our success in rapid and innovative product development to these clinical mentors and we work closely with them for review and clinical feedback. We continue to build clinical partnerships with physicians in emerging markets for needs assessment and securing user feedback on our devices.

Notice: All logos, trademarks are registered trademarks of their respective owners.

We believe that partnerships and collaborations are key requirements for inclusive innovation, and we have cultivated deep relationships with technology partners, clinical partners and hospitals, development partners, and suppliers.

Beyond innovation, meaningful and inclusive collaboration is key to creating sustainable partnerships. Clinical expertise is vital during the early phase of device development. This collaboration ensures that new devices address specific needs and could be effectively integrated into a clinical environment.

The Bioscoop: Our Soft-tissue core biopsy technology was developed in close collaboration with the Stanford-India Biodesign Programme. This is a joint collaborative fellowship programme between The All India Institute of Medical Sciences and Stanford University. Our subsidiary, Indio Labs Private Limited, has acquired worldwide, exclusive licenses for the two technologies developed during the fellowship programme. We have a long-standing association with key opinion leaders in the specialty areas at leading academic medical centers in India and internationally.

We collaborate with these physician mentors at world-class institutions including, The All India Institute of Medical Sciences (New Delhi, India), Stanford Clinics and Hospitals (Stanford University, USA), Johns Hopkins University (Baltimore, USA), National University Hospitals (Singapore), St. John’s Hospital and Research Center (Bangalore, India) and Translational Health Sciences and Technology Institute (Faridabad, India).

Notice: All logos, trademarks are registered trademarks of their respective owners
Technology Partner

We believe that partnerships and collaborations are key requirements for inclusive innovation, and we have cultivated deep relationships with technology partners, clinical partners and hospitals, development partners, and suppliers.

Omya has integrated best and clinically proven Masimo technologies to provide enhanced clinical capabilities in our patient monitoring systems. Accurate sensing and signal processing are necessary components of any patient monitoring system, and Masimo is an innovator in this area for noninvasive and continuous SpO2 monitoring for neonate and in critical care settings.

https://www.masimo.com/oem/partners/omya/

Omya has also integrated Masimo’s (formerly: Phasein, Sweden) Capnography and Multigas monitoring technologies into its range of high-end patient monitoring systems. These systems measure respiratory gases in a wide range of clinical applications reliably thus improving patient outcomes.

Omya’s new critical care ventilator is developed with the advanced module from Demcon Macawi respiratory systems, The Netherlands. These modules are integrated into two models of neonate and critical care ventilators for invasive and non-invasive ICU and sub-acute care areas.

Notice: MasimoSET® and Demcon® are registered trademarks of their respective owners, mentioned hereunder in Purchasing and Licensing Agreement.
Clinical Partner

We believe that partnerships and collaborations are key requirements for inclusive innovation, and we have cultivated deep relationships with technology partners, clinical partners and hospitals, development partners, and suppliers.

Through our subsidiary, Indio Labs Private Limited, we have a long-standing association with key opinion leaders in the specialty areas of gastroenterology, urology, nephrology, oncology, critical care, and pediatrics at leading academic medical centers in India and internationally.

These include physician mentors at world-class institutions including The All India Institute of Medical Sciences (New Delhi, India), Stanford Clinics and Hospitals (Stanford University, USA), Johns Hopkins University (Baltimore, USA), National University Hospitals (Singapore), St. John’s Hospital and Research Center (Bangalore, India) and Translational Health Sciences and Technology Institute (Faridabad, India).

We owe our success in rapid and innovative product development to these clinical mentors and we work closely with them for review and clinical feedback. We continue to build clinical partnerships with physicians in emerging markets for needs assessment and securing user feedback on our devices.

Notice: All logos, trademarks are registered trademarks of their respective owners.
Collaborations

We believe that partnerships and collaborations are key requirements for inclusive innovation, and we have cultivated deep relationships with technology partners, clinical partners and hospitals, development partners, and suppliers.

Beyond innovation, meaningful and inclusive collaboration is key to creating sustainable partnerships. Clinical expertise is vital during the early phase of device development. This collaboration ensures that new devices address specific needs and could be effectively integrated into a clinical environment.

The Bioscoop: Our Soft-tissue core biopsy technology was developed in close collaboration with the Stanford-India Biodesign Programme. This is a joint collaborative fellowship programme between The All India Institute of Medical Sciences and Stanford University. Our subsidiary, Indio Labs Private Limited, has acquired worldwide, exclusive licenses for the two technologies developed during the fellowship programme. We have a long-standing association with key opinion leaders in the specialty areas at leading academic medical centers in India and internationally.

We collaborate with these physician mentors at world-class institutions including, The All India Institute of Medical Sciences (New Delhi, India), Stanford Clinics and Hospitals (Stanford University, USA), Johns Hopkins University (Baltimore, USA), National University Hospitals (Singapore), St. John’s Hospital and Research Center (Bangalore, India) and Translational Health Sciences and Technology Institute (Faridabad, India).

Notice: All logos, trademarks are registered trademarks of their respective owners

Leadership Team

Our core management possesses specialized technology development expertise and decades of combined experience in product development and contract manufacturing services. This experience helps in understanding unmet needs in mid-tier hospitals and the entire medical devices value-chain
null

Tetali Murali Krishna Reddy

Chairman
Main Promoter
Read More
null

Siraj Bagwan

Director
M. Design, Stanford Biodesign
Read More
null

Tetali Murali Krishna Reddy

Chairman – Main Promoter
Board Member

Read More
null

Siraj Bagwan

Director
M. Design, Stanford Biodesign

Read More
null

Ahmed Al Khudair

Strategic Investor, Director

Read More
null

Subrahmanyam Goparaju

Investor, Advisor and Mentor 
Business Strategy and R&D
Read More
null

Jonathan Pillai, Ph.D

Co-inventor and Advisor 
Intellectual Property and Regulatory
Read More
null

Dr. Jagdish Chaturvedi

Co-inventor and Advisor 
Clinical Affairs
Read More
Core Management
null

Tetali Murali Krishna Reddy

Chairman
Main Promoter
Read More
null

Siraj Bagwan

Director
M. Design, Stanford Biodesign
Read More
Board of Directors
null

Tetali Murali Krishna Reddy

Chairman – Main Promoter
Board Member

Read More
null

Siraj Bagwan

Director
M. Design, Stanford Biodesign

Read More
null

Ahmed Al Khudair

Strategic Investor, Director

Read More
Advisors
null

Subrahmanyam Goparaju

Investor, Advisor and Mentor 
Business Strategy and R&D
Read More
null

Jonathan Pillai, Ph.D

Co-inventor and Advisor 
Intellectual Property and Regulatory
Read More
null

Dr. Jagdish Chaturvedi

Co-inventor and Advisor 
Clinical Affairs
Read More

Quality and Compliance

Omya is committed to quality and has established, implemented, and documented its quality management system. This systems approach helps us to ensure total quality most effectively during the design phase, manufacturing, and distribution of our devices.

Quality is a core responsibility of our company. As a medical device manufacturer, care providers, patients, and consumers expect the level of quality we promise through our quality management system. We build quality in our designs, processes, and devices meeting our responsibilities to those we serve while operating efficiently, minimizing risks, and optimizing on cost. We believe the consistent delivery of good quality devices shall help our company to build a trust and brand image with our customers.

Omya understands the critical role of our devices in the diagnosis and treatment of patients. We believe our patients and care providers deserve consistent, reliable, and good-quality products. We focus on quality and compliance throughout our product lifecycle to ensure consistent standards.

Our research and development and manufacturing facility in Whitefield, Bengaluru is certified by Underwriters Laboratories(UL) with Medical Device Quality Management System under International standards ISO 13485:2016.

Scope: Design, Development, manufacturing, and distribution of Syringe Pump, Infusion Pump, Patient Monitor, and Ventilator.

Compliance testing is a critical step in confirming the design output into a clinically reliable product. We collaborate with internationally accredited testing labs for their comprehensive assessment, demonstrating compliance with standards and regulations around the world.

Our devices are tested at various stages during the design and production cycle. These are tested to confirm the devices meet the functionality, usability, and reliability objectives. Also, various other tests are conducted for ergonomics, electrical, mechanical, and functional safety, as well as software testing, to ensure the reliability of design during manufacturing and clinical performance.

Omya’s manufacturing facility at Whitefield in Bengaluru is certified for compliance with various international standards for the environment, safety and various processes of quality, and supply chain. The products manufactured in this facility are tested at various levels before, during the process, and for performance verification and qualification for clinical use.

We have established a procedural approach to ensure our R&D and manufacturing operations comply with our defined management system as well as international guidelines. Our quality processes, continual improvements, quality audits apply to all the functions in R&D and manufacturing as well as our suppliers. We monitor, assess, and identify opportunities to continuously improve the effectiveness of our quality management system audits. In addition to our audits, we conduct Management Reviews to assess the effectiveness of the quality management system and its necessary improvements.

The design in medical device development is paramount for its clinical success. It involves 'design process' and 'design output' that effectively performs its intended function, satisfies the end-users need, complies with regulatory, through a multi-disciplinary and collaborative effort.

We focus on design with a holistic and rigorous process approach to design. We strive to understand the entire patient pathways from the perspective of every primary user: patients, clinicians, nurses, and other stakeholders in the hospital care areas. We execute the design and development process with precision at every stage; conceptualization to compliance, designing to testing, and commercialization to surveillance.

The research and discovery phase allows identifying unmet needs and reviewing the applicable regulations. Based on the needs evaluation, design specifications are developed through collaboration between various multi-disciplinary members such as clinicians, regulatory, user group, engineering teams. Working prototypes are fabricated to test and provide feedback, iterating the design. Effective validation and verification activities are executed to ensure the design output meets the intended use specifications within the regulatory framework. While the design is being finalized, the manufacturing processes are designed in parallel and full-scale production could commence with the design control process.

Quality Certifications

Omya is committed to quality and has established, implemented, and documented its quality management system. This systems approach helps us to ensure total quality most effectively during the design phase, manufacturing, and distribution of our devices.

Quality is a core responsibility of our company. As a medical device manufacturer, care providers, patients, and consumers expect the level of quality we promise through our quality management system. We build quality in our designs, processes, and devices meeting our responsibilities to those we serve while operating efficiently, minimizing risks, and optimizing on cost. We believe the consistent delivery of good quality devices shall help our company to build a trust and brand image with our customers.

Omya understands the critical role of our devices in the diagnosis and treatment of patients. We believe our patients and care providers deserve consistent, reliable, and good-quality products. We focus on quality and compliance throughout our product lifecycle to ensure consistent standards.

Our research and development and manufacturing facility in Whitefield, Bengaluru is certified by Underwriters Laboratories(UL) with Medical Device Quality Management System under International standards ISO 13485:2016.

Scope: Design, Development, manufacturing, and distribution of Syringe Pump, Infusion Pump, Patient Monitor, and Ventilator.

Testing & Compliance

Compliance testing is a critical step in confirming the design output into a clinically reliable product. We collaborate with internationally accredited testing labs for their comprehensive assessment, demonstrating compliance with standards and regulations around the world.

Our devices are tested at various stages during the design and production cycle. These are tested to confirm the devices meet the functionality, usability, and reliability objectives. Also, various other tests are conducted for ergonomics, electrical, mechanical, and functional safety, as well as software testing, to ensure the reliability of design during manufacturing and clinical performance.

Omya’s manufacturing facility at Whitefield in Bengaluru is certified for compliance with various international standards for the environment, safety and various processes of quality, and supply chain. The products manufactured in this facility are tested at various levels before, during the process, and for performance verification and qualification for clinical use.

We have established a procedural approach to ensure our R&D and manufacturing operations comply with our defined management system as well as international guidelines. Our quality processes, continual improvements, quality audits apply to all the functions in R&D and manufacturing as well as our suppliers. We monitor, assess, and identify opportunities to continuously improve the effectiveness of our quality management system audits. In addition to our audits, we conduct Management Reviews to assess the effectiveness of the quality management system and its necessary improvements.

Design Excellence

The design in medical device development is paramount for its clinical success. It involves 'design process' and 'design output' that effectively performs its intended function, satisfies the end-users need, complies with regulatory, through a multi-disciplinary and collaborative effort.

We focus on design with a holistic and rigorous process approach to design. We strive to understand the entire patient pathways from the perspective of every primary user: patients, clinicians, nurses, and other stakeholders in the hospital care areas. We execute the design and development process with precision at every stage; conceptualization to compliance, designing to testing, and commercialization to surveillance.

The research and discovery phase allows identifying unmet needs and reviewing the applicable regulations. Based on the needs evaluation, design specifications are developed through collaboration between various multi-disciplinary members such as clinicians, regulatory, user group, engineering teams. Working prototypes are fabricated to test and provide feedback, iterating the design. Effective validation and verification activities are executed to ensure the design output meets the intended use specifications within the regulatory framework. While the design is being finalized, the manufacturing processes are designed in parallel and full-scale production could commence with the design control process.

Menu